Symrise
This article was originally published in The Rose Sheet
Executive Summary
James Forman appointed CEO and president of flavors and fragrance supplier as company moves beyond integration phase into preparing for an initial public offering within the next three to four years, Holzminden, Germany firm reports Sept. 15. Effective Oct. 1, Forman will succeed Horst-Otto Gerberding, who will become vice chairman of the board. Gerberding's role as CEO and president was intended as an interim position during the integration phase of the Dragoco and Haarmann & Reimer businesses (1"The Rose Sheet" Oct. 14, 2002, In Brief). Gerberding will continue to help oversee the company's strategic direction and position it for the IPO. Forman most recently served as CEO of consumer products company Stollwerck AG...
You may also be interested in...
Symrise CEO
Gerold Linzbach to CEO effective March 1, succeeding James Forman, who has stepped down by mutual agreement, Holzminden, Germany flavors and fragrance supplier announces Feb. 11. Linzbach, who previously served as president of Invista Resins & Fibers in the U.S., will benefit Symrise with his extensive experience in strategic realignment, the firm notes. Exec assumes role as company moves to expand its global business and further strengthen its relationship with clients, according to Symrise. Forman led the company through its final phase of integration following its creation by the 2002 merger of Dragoco and Haarmann & Reimer (1"The Rose Sheet" Sept. 22, 2003, In Brief)...
H&R/Dragoco management
Combined fragrance and flavors businesses, acquired by Swedish EQT Northern Europe Equity Funds, will be headed by Horst-Otto Gerberding as CEO, firm says following close of transaction Oct. 1. Among other management team appointments, Dan Stebbins will be in charge of flavors, while Tim Schaffner will head fragrances and cosmetics. Horst Finkelmeier will oversee aroma chemicals, Heinz-Jurgen Bertram will be in charge of R&D, Jurgen Nienhaus is named head of operations, and Martin Wolf is chief financial officer. Merger received clearance from European Commission in September (1"The Rose Sheet" Sept. 23, 2002, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”